NCT06006598View on ClinicalTrials.gov

A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

May 5, 2024

Study Completion Date

May 5, 2024

Conditions
Healthy
Interventions
DRUG

BI 1584862

BI 1584862

DRUG

Placebo matching BI 1584862

Placebo matching BI 1584862

DRUG

midazolam

midazolam

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06006598 - A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men | Biotech Hunter | Biotech Hunter